Glenmark Gets USFDA Nod For Generic Diabetes Treatment Drug
Facebook Twitter google+ RSS Feed

Glenmark Gets USFDA Nod For Generic Diabetes Treatment Drug

Friday, 29 May 2015, 11:05 Hrs
32
cmt right
22
Comment Right
45
cmt right
6
cmt right
Printer Print Email Email


BENGALURU: Glenmark Pharmaceuticals said it has received the final approval from U.S. health regulator for its generic version of desmopressin acetate tablets used in treatment of diabetes and bed-wetting.



The approval by the U.S. Food and Drug Administration is for strengths of 0.1 mg and 0.2 mg and the company plans to commence shipping the tablets to the US immediately, the pharma company said in a statement.



Desmopressin Acetate is sold under the trademark DDAVP by Ferring Pharmaceuticals. Citing IMS data, Glenmark said, "DDAVP market achieved annual sales of  approximately $72.1 million" in the 12 month period.



Glenmark's current portfolio consists of 97 productsauthorised for distribution in the U.S. and 68 abbreviated new drug approvals with the USFDA. Shares of Glenmark Pharmaceuticals were trading at 874.75 per scrip in afternoon trade, up 2.04 per cent from the previous close on the BSE.
Also Read:
High Job Potential Sectors To Be Opened Up For FDI: PM Modi
Renewable Energy Gains Momentum In India: U.S.


Source: PTI
Experts on SiliconIndia
Santhosh  K
Sr. Soft. Engg.
Oracle India
Nehal Vyas
Sr. Team Lead
Cyberoam Tech.
Rani Malli
Sr. Director
Philips
Sr. Executive
ISB
Vijay Balkrishna Konduskar
Business Consultant
Imans Web Tech
Dr L P  Sharma
Technical Director
NIC
Reena Khanna
Founder
Solitaireworld
Dellas  Asse
sys-network admin
Computer Station
Write your comment now
Submit Reset
SPOTLIGHT